# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Citigroup analyst Ashiq Mubarack maintains Mersana Therapeutics (NASDAQ:MRSN) with a Buy and lowers the price target from $6...
Baird analyst Colleen Kusy maintains Mersana Therapeutics (NASDAQ:MRSN) with a Neutral and lowers the price target from $4 t...
Mersana Therapeutics (NASDAQ:MRSN) reported quarterly losses of $(0.20) per share which missed the analyst consensus estimate o...
Mersana Therapeutics (NASDAQ:MRSN) reported quarterly losses of $(0.16) per share which beat the analyst consensus estimate of ...
JP Morgan analyst Brian Cheng upgrades Mersana Therapeutics (NASDAQ:MRSN) from Underweight to Neutral and announces $5 price...